Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
CAMBRIDGE, Mass., Feb. 04, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 11, 2016 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2015. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
Interested participants and investors may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 35553440. To join the live webcast please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
